The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for the patients. This project has received funding of 5.0 MSEK from the VINNOVA program ”Innovative small and medium sized enterprises”.
Parkinson’s disease is one of the most prevalent neurological disorders with a significant unmet medical need. World-wide more than 4.6 million individuals over the age of 50 suffer from Parkinson’s disease and it is estimated that the number will more than double by 2030. Today, only symptomatic therapies are available for Parkinson’s disease and there is a huge unmet medical need for treatments that slow or halt the progression of the disease.
BioArctic is developing a new type of therapy for Parkinson’s disease, with the potential of becoming the first treatment on the market with an effect on the disease progression and improved quality of life for the patients. The novel treatment concept is based on removing or inactivating the neurotoxic protofibril/oligomer forms of alpha-synuclein with a humanized monoclonal antibody, BAN0805.
In the Parkinson´s disease program, BioArctic has close collaboration with Uppsala University and other Swedish universities in Lund, Linköping, Gothenburg and with Karolinska Institutet.
“We are grateful for the support from Vinnova and are progressing the Parkinson´s disease program with this innovative treatment further towards the clinic, intended to delay the progression of the disease and improve the quality of life for Parkinson´s disease patients”, says Dr. Gunilla Osswald, CEO of BioArctic Neuroscience AB.
For further information, please contact:
BioArctic Neuroscience AB
Gunilla Osswald, CEO
Phone: +46 8 695 69 31